Huaier Granule in Patients With Stage I Primary Ovarian Fallopian Tube Cancer After Peritoneal Cancer

Inclusion Criteria: 1. ≥18years old 2. Histopathologically confirmed FIGO II-IV stage primary ovarian cancer peritoneal or fallopian tube cancer 3. Patients who underwent primary tumor reduction or intermediate tumor reduction with satisfactory results (R0/R1) within 15 days after surgery 4. After tumor reduction, the physician assessed that chemotherapy was not suitable or the patient was unwilling to receive chemotherapy 5. Life expectancy is 3 months 6. Liver and kidney function : 1. AST and ALT 3 times the upper limit of normal value or 5 times the upper limit of normal value in the presence of liver metastasis; T 2. he upper limit of total bilirubin 3 times normal value; 3. Serum creatinine is 3 times the upper limit of normal 7. No other tumors, no history of other malignant tumors (except non-melanoma skin cancer in situ cervical cancer or other cancers that have received curative treatment and have no signs of disease for at least 5 years) 8. Voluntarily participate in the study and sign the informed consent Exclusion Criteria: 1. Breastfeeding women during pregnancy 2. Recurrent ovarian cancer 3. Known allergy to the study drug; 4. Central nervous system diseases or brain metastases; 5. History of abdominal/pelvic radiotherapy; 6. History of organ transplantation history of immune deficiency disease requiring systemic steroid therapy or other immunosuppressive therapy 7. Hiv-ag /AB test result is positive; 8. Complicated with serious cardiovascular and cerebrovascular diseases or other serious diseases affecting follow-up treatment of subjects: such as myocardial infarction, unstable angina, stroke or transient ischemic attack within 6 months; Uncontrolled hypertension after antihypertensive therapy (systolic ≥140 or diastolic ≥90 mmHg); Uncontrolled diabetes mellitus (HbA1c\>8.0%) etc 9. Participate in other clinical study patients within 1 month 10. Poor compliance is estimated to be difficult to complete the follow-up 11. In addition to the above, the investigator determined that the patients were not suitable for the clinical trial